AI assistant
Saniona — Share Issue/Capital Change 2020
Jun 30, 2020
3195_rns_2020-06-30_e938ea98-653e-45af-aa17-eb1478ce2ed2.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
saniona
PRESS RELEASE
June 30, 2020
Change in numbers of shares and votes in Saniona AB (publ)
During June, the registered number of shares and votes in Saniona AB (publ) ("Saniona") has increased due to the exercising of warrants of series TO 1. As of June 30, 2020, the registered number of shares and votes in Saniona amounts to 30,383,316.
For more information, please contact
Rami Levin, President & CEO, Saniona, Mobile: +1 (781) 987 3144, Email: [email protected]
Anita Milland, Interim CFO & Head of IR, Mobile +45-20163432, Email: [email protected]
This information is such information as Saniona AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 8:00 p.m. CET on June 30, 2020.
About Saniona
Saniona is a rare disease biopharmaceutical company focused on research, development and commercialization of treatments for the central nervous system. The company has four programs in clinical development. Saniona intends to develop and commercialize treatments for rare disease indications such as Prader-Willi syndrome and hypothalamic obesity on its own. The research is focused on ion channels and the company has a broad portfolio of research programs. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The company's shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Saniona AB (publ), Baltorpvej 154, DK-2750 Ballerup, Denmark
Web: saniona.com Email: [email protected]